Zydus Lifesciences Ltd.

Financial

	Zydus Lifesciences	Lupin	Cipla
Operational Metrics
API Sector
US DMF Filings	135.0 .	157.0 .	1704.0 .
Pharmaceutical Sector
Number of ANDA's Filed in USA	460.0 .	431.0 .	277.0 .
Number of ANDA's Approved By USFDA	402.0 .	314.0 .	196.0 .
Domestic Sales Growth - YoY	6.6 %	8.1 %	9.1 %
R&D as a % of Total Sales	6.4 %	8.7 %	7.2 %
Financials
5 yr Average ROE	16.63 %	0.39 %	11.43 %
5yr average Equity Multiplier	1.82	1.85	1.39
5yr Average Asset Turnover Ratio	0.62	0.66	0.76
5yr Avg Net Profit Margin	15.64 %	0.74 %	10.96 %
Price to Book	5.55	5.2	4.48
P/E	28.54	38.84	29.06
5yr Avg Cash Conversion Cycle	-65.67 Days	-27.27 Days	-3.69 Days
Inventory Days	51.98 Days	51.43 Days	59.85 Days
Days Receivable	41.75 Days	56.09 Days	44.13 Days
Days Payable	168.09 Days	155.83 Days	114.64 Days
5yr Average Interest Coverage Ratio	15.34	3.33	23.71
5yr Avg ROCE	16.69 %	6.39 %	15.24 %
5yr Avg Operating Profit Margin	23.13 %	13.98 %	22.51 %
5 yr average Debt to Equity	0.44	0.43	0.13
5yr CAGR Net Profit	1.18 %	-6.65 %	12.9 %
5yr Average Return on Assets	9.5 %	0.23 %	8.36 %
Shareholdings
Promoter Holding	74.98 %	47.01 %	33.47 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.1 %	0.15 %	-3.26 %
Change in Mutual Fund Holding (3 Yrs)	0.3 %	3.77 %	2.19 %

Business

	Zydus Lifesciences	Lupin	Cipla
Product Wise Break-Up	Product Wise Break-Up US Formulations 47.0 India Formulations 26.0 Wellness 14.0 Emerging Markets 9.0 Active Pharmaceutical Ingredient (API) 3.0 Alliance 1.0 Europe Formulatios 0 Animal Health 0 EMB Formulations 0 USA 0 Developed Markets 0 NCE licensing income 0 India 0 Emerging Market Formulation 0 Advanced Markets Formulations 0 Generic FDF 0 Custom Synthesis 0 New ventures 0 Pharmaceuticals 0	Product Wise Break-Up New ventures 0 Developed Markets 0 Alliance 0 Pharmaceuticals 0 Wellness 0 Europe Formulatios 0 Custom Synthesis 0 USA 0 India 34.0 NCD 1.0 Active Pharmaceutical Ingredient (API) 0 Generic FDF 0 Emerging Market 12.0 Emerging Markets 0 Animal Health 0 US Formulations 0 Advanced Markets Formulations 45.0 India Formulations 0 EMB Formulations 0 Others 8.0	Product Wise Break-Up New ventures 3.43 Developed Markets 0 Alliance 0 Pharmaceutical 96.57 Wellness 0 Europe Formulatios 0 Custom Synthesis 0 USA 0 India 0 NCE licensing income 0 Active Pharmaceutical Ingredient (API) 0 Generic FDF 0 Emerging Market Formulation 0 Emerging Markets 0 Animal Health 0 US Formulations 0 Advanced Markets Formulations 0 India Formulations 0 EMB Formulations 0
Segment Break-Up	Segment Break-Up Pharmaceuticals 85.91 OTC 14.09 Research Services & Sale of IP`s 0	Segment Break-Up OTC 0 Pharmaceuticals 100.0 Research Services & Sale of IP`s 0	-
Location Wise Break-Up	Location Wise Break-Up India 44.32 USA 43.43 API 0 EMEA 0 Growth Markets 0 Japan 0 SAGA 0 Europe 0 Global API 0 Rest of the World 0 Emerging Markets 0 North America 0 Others 12.25	Location Wise Break-Up India 33.0 SAGA 0 Global API 0 EMEA 11.0 Japan 0 Emerging Markets 0 North America 0 Developed Markets 10.0 Rest of the World 0 API 5.0 Europe 0 USA 39.0 Others 2.0	Location Wise Break-Up India 44.0 SAGA 12.0 Global API 2.0 EMEA 0 Japan 0 Emerging Markets 0 North America 29.0 Growth Markets 0 Rest of the World 11.0 API 0 Europe 0 USA 0 Others 2.0
Operating Profit Break-Up	Operating Profit Break-Up Pharmaceuticals 90.54 OTC 9.46 New Ventures 0	-	Operating Profit Break-Up OTC 0 Pharmaceuticals 100.0 New Ventures 0
Therapeutic Area Break-Up	Therapeutic Area Break-Up Cardiac Science 15.0 Respiratory Systems 14.0 Anti-Infective 12.0 Gastro Intestinal 10.0 Pain Management 8.0 Gynecology 7.0 Dermatology 6.0 Others 28.0	-	-
Asset Break-Up	Asset Break-Up USA 93.14 India 2.8 South Africa 0 Others 4.06	-	Asset Break-Up India 47.79 South Africa 16.85 USA 30.05 Others 5.31

Zydus Lifesciences Ltd.

SIGN UP FOR FREE